FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892235917> ?p ?o ?g. }

• W2892235917 endingPage "TPS9605" @default.
• W2892235917 startingPage "TPS9605" @default.
• W2892235917 abstract "TPS9605 Background: Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer. MCC with clinically detected lymph node (LN) metastases is associated with high risk of systemic recurrence despite initial surgical therapy and/or radiation therapy (RT). Adjuvant cytotoxic chemotherapy is not associated with overall survival benefit in stage III MCC and there is a strong unmet need for effective adjuvant systemic therapy. Clinical investigation of PD-1/PD-L1 blockade in patients with metastatic MCC is associated with remarkable improvement in clinical outcomes with response rates > 50% in a chemotherapy-naïve setting. This notable benefit from PD-1 blockade in stage IV MCC, along with the recent success with adjuvant PD-1 blockade in stage III melanoma, together provide strong rationale for investigating avelumab, an anti-PD-L1 antibody, for adjuvant systemic therapy in MCC patients with high risk of recurrence. Methods: The ADAM (Adjuvant Avelumab in Merkel) trial is an investigator-sponsored, phase 3, multi-center, double-blinded and placebo-controlled study. We plan to enroll 100 MCC patients with clinically or radiologically detected LN metastases treated definitively with surgery (with or without adjuvant RT). Patients will be randomized (1:1) to receive either avelumab or placebo administered IV at a dose of 10mg/kg every 15 days for the first 4 months, then once monthly for the next 4 months, and then once every 4 months. Treatment will end 2 years after starting the study drug, or upon recurrence of disease, unacceptable toxicity, or study withdrawal. The primary endpoint is relapse-free survival. Secondary endpoints include overall survival, disease-specific survival, distant metastasis-free survival, and safety and tolerability. Exploratory endpoints include tissue and blood-based biomarkers and AMERK (Anti-Merkel polyomavirus) serology as a recurrence predictor in a prospective, multi-center setting. The ADAM trial represents the first-ever phase 3 trial in MCC and is a major academic collaboration across several US cancer centers. Clinical trial information: NCT03271372." @default.
• W2892235917 created "2018-09-27" @default.
• W2892235917 creator A5001901126 @default.
• W2892235917 creator A5008866438 @default.
• W2892235917 creator A5017642748 @default.
• W2892235917 creator A5023622812 @default.
• W2892235917 creator A5023949296 @default.
• W2892235917 creator A5024680009 @default.
• W2892235917 creator A5028479135 @default.
• W2892235917 creator A5033634015 @default.
• W2892235917 creator A5034066580 @default.
• W2892235917 creator A5034665205 @default.
• W2892235917 creator A5034786338 @default.
• W2892235917 creator A5035539932 @default.
• W2892235917 creator A5036875036 @default.
• W2892235917 creator A5036949080 @default.
• W2892235917 creator A5037908919 @default.
• W2892235917 creator A5039497310 @default.
• W2892235917 creator A5061209536 @default.
• W2892235917 creator A5078755190 @default.
• W2892235917 creator A5082643048 @default.
• W2892235917 creator A5089516753 @default.
• W2892235917 date "2018-05-20" @default.
• W2892235917 modified "2023-10-01" @default.
• W2892235917 title "ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372." @default.
• W2892235917 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.tps9605" @default.
• W2892235917 hasPublicationYear "2018" @default.
• W2892235917 type Work @default.
• W2892235917 sameAs 2892235917 @default.
• W2892235917 citedByCount "5" @default.
• W2892235917 countsByYear W28922359172018 @default.
• W2892235917 countsByYear W28922359172019 @default.
• W2892235917 countsByYear W28922359172020 @default.
• W2892235917 countsByYear W28922359172021 @default.
• W2892235917 countsByYear W28922359172023 @default.
• W2892235917 crossrefType "journal-article" @default.
• W2892235917 hasAuthorship W2892235917A5001901126 @default.
• W2892235917 hasAuthorship W2892235917A5008866438 @default.
• W2892235917 hasAuthorship W2892235917A5017642748 @default.
• W2892235917 hasAuthorship W2892235917A5023622812 @default.
• W2892235917 hasAuthorship W2892235917A5023949296 @default.
• W2892235917 hasAuthorship W2892235917A5024680009 @default.
• W2892235917 hasAuthorship W2892235917A5028479135 @default.
• W2892235917 hasAuthorship W2892235917A5033634015 @default.
• W2892235917 hasAuthorship W2892235917A5034066580 @default.
• W2892235917 hasAuthorship W2892235917A5034665205 @default.
• W2892235917 hasAuthorship W2892235917A5034786338 @default.
• W2892235917 hasAuthorship W2892235917A5035539932 @default.
• W2892235917 hasAuthorship W2892235917A5036875036 @default.
• W2892235917 hasAuthorship W2892235917A5036949080 @default.
• W2892235917 hasAuthorship W2892235917A5037908919 @default.
• W2892235917 hasAuthorship W2892235917A5039497310 @default.
• W2892235917 hasAuthorship W2892235917A5061209536 @default.
• W2892235917 hasAuthorship W2892235917A5078755190 @default.
• W2892235917 hasAuthorship W2892235917A5082643048 @default.
• W2892235917 hasAuthorship W2892235917A5089516753 @default.
• W2892235917 hasConcept C121608353 @default.
• W2892235917 hasConcept C126322002 @default.
• W2892235917 hasConcept C141071460 @default.
• W2892235917 hasConcept C142724271 @default.
• W2892235917 hasConcept C143998085 @default.
• W2892235917 hasConcept C203092338 @default.
• W2892235917 hasConcept C204787440 @default.
• W2892235917 hasConcept C27081682 @default.
• W2892235917 hasConcept C2776694085 @default.
• W2892235917 hasConcept C2777381376 @default.
• W2892235917 hasConcept C2777546739 @default.
• W2892235917 hasConcept C2777701055 @default.
• W2892235917 hasConcept C2777863537 @default.
• W2892235917 hasConcept C2777982462 @default.
• W2892235917 hasConcept C2778342957 @default.
• W2892235917 hasConcept C2780057760 @default.
• W2892235917 hasConcept C2780291066 @default.
• W2892235917 hasConcept C2780849966 @default.
• W2892235917 hasConcept C535046627 @default.
• W2892235917 hasConcept C71924100 @default.
• W2892235917 hasConceptScore W2892235917C121608353 @default.
• W2892235917 hasConceptScore W2892235917C126322002 @default.
• W2892235917 hasConceptScore W2892235917C141071460 @default.
• W2892235917 hasConceptScore W2892235917C142724271 @default.
• W2892235917 hasConceptScore W2892235917C143998085 @default.
• W2892235917 hasConceptScore W2892235917C203092338 @default.
• W2892235917 hasConceptScore W2892235917C204787440 @default.
• W2892235917 hasConceptScore W2892235917C27081682 @default.
• W2892235917 hasConceptScore W2892235917C2776694085 @default.
• W2892235917 hasConceptScore W2892235917C2777381376 @default.
• W2892235917 hasConceptScore W2892235917C2777546739 @default.
• W2892235917 hasConceptScore W2892235917C2777701055 @default.
• W2892235917 hasConceptScore W2892235917C2777863537 @default.
• W2892235917 hasConceptScore W2892235917C2777982462 @default.
• W2892235917 hasConceptScore W2892235917C2778342957 @default.
• W2892235917 hasConceptScore W2892235917C2780057760 @default.
• W2892235917 hasConceptScore W2892235917C2780291066 @default.
• W2892235917 hasConceptScore W2892235917C2780849966 @default.
• W2892235917 hasConceptScore W2892235917C535046627 @default.
• W2892235917 hasConceptScore W2892235917C71924100 @default.
• W2892235917 hasIssue "15_suppl" @default.
• W2892235917 hasLocation W28922359171 @default.

• next